

GOVERNMENT OF INDIA
DEPARTMENT OF ATOMIC ENERGY
RAJYA SABHA
UNSTARRED QUESTION NO-2248
ANSWERED ON 20/03/2025

TABLET FOR CANCER PATIENTS

2248. MS. INDU BALA GOSWAMI

Will the Prime Minister be pleased to state:-

- (a) whether the Department of Atomic Energy (DAE) has brought out any tablet which can safeguard cancer patients from the side effects of radiotherapy;
- (b) if so, the details thereof; and
- (c) whether the said tablet has been approved by the Food Safety and Standards Authority of India, if so, the details thereof?

ANSWER

THE MINISTER OF STATE FOR PERSONNEL, PUBLIC GRIEVANCES AND PENSIONS AND IN THE PMO (DR. JITENDRA SINGH)

- (a)&(b) Yes, the Department of Atomic Energy in collaboration with M/s. IDRS Labs Pvt. Ltd. Bengaluru has launched a Food Supplement/Nutraceutical AKTOCYTE which is aimed at enhancing the quality of life for cancer patients undergoing radiotherapy. Scientists from Bhabha Atomic Research Centre, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai, Tata Memorial Hospital, Mumbai; and M/s. IDRS Labs were involved in the making of the tablets. This product will be an important contribution towards affordable cancer care in India.

The AKTOCYTE tablets have shown good results in phase II clinical trial particularly in pelvic cancer patients suffering from radiotherapy-induced side effects. Patients treated with AKTOCYTE tablets demonstrated an extraordinary recovery from radiotherapy mediated toxicity. The tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator and antioxidant, mark a significant advancement in cancer care. However, further confirmatory clinical trials are being conducted conclusively prove its benefit.

- (c) Yes, AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI) as a nutraceutical health supplement.
